MedTrace Logo

Evaluation of Protein in the Urine in Patients Receiving Bevacizumab

NCT00849394 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 106

Last updated 2012-11-01

No results posted yet for this study

Summary

This is a clinical research study to look at the incidence of proteinuria (a condition in which urine contains an abnormal amount of protein) caused by shortened infusions (given into the vein over 10 or 15 minutes) of bevacizumab (a medication prescribed for colon, lung, or breast cancer). There are currently no published studies or clinical data looking at how safe shortened infusions of bevacizumab are in relationship to the side effect of proteinuria. We hypothesis that shortened infusions of bevacizumab will result in an increased risk for proteinuria compared to the standard infusions of this agent.

Conditions

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    collaborator OTHER

  • North Texas Veterans Healthcare System

    lead FED

Principal Investigators

  • Sachin Shah, Pharm.D. · Texas Tech University Health Sciences Center School of Pharmacy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00849394 on ClinicalTrials.gov